{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:17:32Z","timestamp":1788380252857,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["GSK Study ID 218363"],"award-info":[{"award-number":["GSK Study ID 218363"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40121-024-00980-9","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T19:01:32Z","timestamp":1716663692000},"page":"1515-1530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-066X","authenticated-orcid":false,"given":"Amir S.","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"980_CR1","unstructured":"World Health Organization. Hepatitis B factsheet 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"issue":"4","key":"980_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/hep.29323","volume":"66","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66(4):1296\u2013313.","journal-title":"Hepatology"},{"issue":"1","key":"980_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","volume":"18","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J. 2021;18(1):114.","journal-title":"Virol J"},{"key":"980_CR4","doi-asserted-by":"crossref","unstructured":"Ghany MG, Buti M, Lampertico P, Lee HM, AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV\/HDV treatment endpoints conference. Hepatology. 2023.","DOI":"10.1097\/HEP.0000000000000431"},{"key":"980_CR5","unstructured":"Food and Drug Administration. Chronic hepatitis B virus infection: developing drugs for treatment guidance for industry 2022. https:\/\/www.fda.gov\/media\/117977\/download."},{"issue":"1","key":"980_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep4.1476","volume":"4","author":"A Loglio","year":"2020","unstructured":"Loglio A, Lampertico P. How durable is functional cure (hepatitis B surface antigen loss) in patients with chronic hepatitis b treated with current antivirals? Hepatol Commun. 2020;4(1):5\u20137.","journal-title":"Hepatol Commun"},{"issue":"10161","key":"980_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"issue":"10","key":"980_CR8","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","volume":"27","author":"MF Yuen","year":"2021","unstructured":"Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021;27(10):1725\u201334.","journal-title":"Nat Med"},{"issue":"21","key":"980_CR9","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387(21):1957\u201368.","journal-title":"N Engl J Med"},{"issue":"10","key":"980_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpdd.1154","volume":"11","author":"K Han","year":"2022","unstructured":"Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, et al. Preclinical and phase 1 assessment of antisense oligonucleotide bepirovirsen in hepatitis B virus-transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses. Clin Pharmacol Drug Dev. 2022;11(10):1191\u2013202.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"980_CR11","unstructured":"Ismail M, Van Wart S, Mager DE. Abstr 10062. Finch Studio: a next generation NONMEM modeling workbench. PAGE 302022."},{"issue":"3","key":"980_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Prog Biomed"},{"issue":"4","key":"980_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10928-014-9368-y","volume":"41","author":"G Koch","year":"2014","unstructured":"Koch G, Krzyzanski W, P\u00e9rez-Ruixo JJ, Schropp J. Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. J Pharmacokinet Pharmacodyn. 2014;41(4):291\u2013318.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"980_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2009;5(4):381\u201391.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"980_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"980_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1124\/dmd.31.11.1419","volume":"31","author":"RS Geary","year":"2003","unstructured":"Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2\u2032-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos. 2003;31(11):1419\u201328.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"980_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/nat.2019.0822","volume":"30","author":"RZ Yu","year":"2020","unstructured":"Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, et al. Population pharmacokinetic\u2013pharmacodynamic modeling of inotersen, an antisense oligonucleotide for treatment of patients with hereditary transthyretin amyloidosis. Nucl Acid Ther. 2020;30(3):153\u201363.","journal-title":"Nucl Acid Ther"},{"issue":"1","key":"980_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10928-019-09619-6","volume":"46","author":"H Xu","year":"2019","unstructured":"Xu H, Tong X, Mugundu G, Scott ML, Cook C, Arfvidsson C, et al. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. J Pharmacokinet Pharmacodyn. 2019;46(1):65\u201374.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"980_CR19","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/bcp.13287","volume":"83","author":"AY Edwards","year":"2017","unstructured":"Edwards AY, Elgart A, Farrell C, Barnett-Griness O, Rabinovich-Guilatt L, Spiegelstein O. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects. Br J Clin Pharmacol. 2017;83(9):1932\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"980_CR20","unstructured":"Food and Drug Administration. Center for drug evaluation and research clinical pharmacology and biopharmaceutics review\u2014Mipomersen. FDA; 2012."},{"key":"980_CR21","unstructured":"European Medicines Agency. Assessment report\u2014Volanesorsen. EMA; 2019."},{"issue":"6","key":"980_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","volume":"9","author":"O Olafuyi","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6): e00890.","journal-title":"Pharmacol Res Perspect"}],"updated-by":[{"DOI":"10.1007\/s40121-024-01066-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00980-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:00:57Z","timestamp":1730106057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00980-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00980-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40121-024-01066-2","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-024-01066-2","URL":"https:\/\/doi.org\/10.1007\/s40121-024-01066-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ahmed Nader, Amir S Youssef, Kelong Han, and Mindy Magee are employees of GSK and hold stocks\/shares in GSK. Mohamed Ismail is an employee of Enhanced Pharmacodynamics LLC and clinical pharmacology and pharmacometrics consultants supporting EOP2 analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained for each study. The studies were conducted in accordance with the International Council on Harmonization Guideline for Good Clinical Practice and the Declaration of Helsinki. The study protocols, any amendments, informed consent, and other information that required pre-approval were reviewed and approved by a national, regional, or investigational center ethics committee or institutional review board, in accordance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements, including US 21 Code of Federal Regulations (CFR) 312.3(b) for constitution of independent ethics committees. Each study obtained written informed consent from each participant prior to any study-specific procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}